GTPBP2

Across TCGA pan-cancer cohorts, GTPBP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GTPBP2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher GTPBP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GTPBP2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SKCM, COAD, and BLCA are the cancer types where GTPBP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.234	0.788	<.001	30	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
BLCA	OS	Median	II,III,IV	1.000	0.414	.035	9	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GTPBP2–SKCM (OS)

Open the SKCM breakdown →